JP2011520989A5 - - Google Patents

Info

Publication number

JP2011520989A5

JP2011520989A5 JP2011510745A JP2011510745A JP2011520989A5 JP 2011520989 A5 JP2011520989 A5 JP 2011520989A5 JP 2011510745 A JP2011510745 A JP 2011510745A JP 2011510745 A JP2011510745 A JP 2011510745A JP 2011520989 A5 JP2011520989 A5 JP 2011520989A5

Authority

JP

Japan

Prior art keywords

antigen

binding protein

binding fragment

binding

pharmaceutical composition

Prior art date

2009-05-26

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 102000023732 binding proteins Human genes 0.000 claims 50
• 108091008324 binding proteins Proteins 0.000 claims 50
• 239000000427 antigen Substances 0.000 claims 48
• 102000036639 antigens Human genes 0.000 claims 48
• 108091007433 antigens Proteins 0.000 claims 48
• 239000012634 fragment Substances 0.000 claims 48
• 239000008194 pharmaceutical composition Substances 0.000 claims 26
• 239000002773 nucleotide Substances 0.000 claims 17
• 125000003729 nucleotide group Chemical group 0.000 claims 17
• 101001010593 Homo sapiens Interleukin-21 receptor Proteins 0.000 claims 14
• 102100030704 Interleukin-21 Human genes 0.000 claims 12
• 108010074108 interleukin-21 Proteins 0.000 claims 12
• 206010025135 lupus erythematosus Diseases 0.000 claims 12
• 210000004027 cell Anatomy 0.000 claims 10
• 230000000694 effects Effects 0.000 claims 8
• 210000002865 immune cell Anatomy 0.000 claims 8
• 230000001404 mediated effect Effects 0.000 claims 8
• 108010017411 Interleukin-21 Receptors Proteins 0.000 claims 6
• 102000004527 Interleukin-21 Receptors Human genes 0.000 claims 6
• 125000003275 alpha amino acid group Chemical group 0.000 claims 6
• 230000035755 proliferation Effects 0.000 claims 6
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 4
• 150000001413 amino acids Chemical class 0.000 claims 4
• 210000003719 b-lymphocyte Anatomy 0.000 claims 4
• 239000003814 drug Substances 0.000 claims 4
• 238000004519 manufacturing process Methods 0.000 claims 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 claims 2
• 102000025171 antigen binding proteins Human genes 0.000 claims 2
• 108091000831 antigen binding proteins Proteins 0.000 claims 2
• 230000004663 cell proliferation Effects 0.000 claims 2
• 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 2
• 102000047008 human IL21R Human genes 0.000 claims 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
• 230000002401 inhibitory effect Effects 0.000 claims 1